John G Ullman & Associates Inc. Has $3.65 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• John G Ullman & Associates Inc. reduced its stake in Pfizer Inc. by 42.3%, thereafter holding 150,703 shares valued at $3.65 million.
• Several institutional investors increased their holdings in Pfizer, with 68.36% of the company's stock now owned by hedge funds and other investors.
• Pfizer declared a quarterly dividend of $0.43 per share, yielding 7.0%, with the ex-dividend date on November 7th.

John G Ullman & Associates Inc. cut its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 42.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 150,703 shares of the biopharmaceutical company's stock after selling 110,464 shares during the period. John G Ullman & Associates Inc.'s holdings in Pfizer were worth $3,653,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. First Bancorp Inc ME grew its holdings in shares of Pfizer by 6.7% during the second quarter. First Bancorp Inc ME now owns 18,215 shares of the biopharmaceutical company's stock valued at $442,000 after buying an additional 1,145 shares in the last quarter. TrueMark Investments LLC grew its holdings in shares of Pfizer by 3.6% during the second quarter. TrueMark Investments LLC now owns 110,930 shares of the biopharmaceutical company's stock valued at $2,689,000 after buying an additional 3,807 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Pfizer during the second quarter valued at $9,582,000. Signature Estate & Investment Advisors LLC grew its holdings in shares of Pfizer by 19.3% during the second quarter. Signature Estate & Investment Advisors LLC now owns 22,976 shares of the biopharmaceutical company's stock valued at $557,000 after buying an additional 3,722 shares in the last quarter. Finally, United Bank grew its holdings in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company's stock valued at $1,408,000 after buying an additional 6,415 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Bank of America lifted their price target on Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Wall Street Zen downgraded Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. UBS Group restated a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Weiss Ratings restated a "hold (c-)" rating on shares of Pfizer in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $28.13.

Pfizer Stock Performance

PFE opened at $24.52 on Friday. The company has a market cap of $139.38 billion, a PE ratio of 13.04, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The stock has a 50-day moving average of $24.89 and a 200-day moving average of $24.11. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.36. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer's dividend payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.